Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Surmodics Inc (NQ: SRDX )

33.33 +7.64 (+29.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Surmodics Inc

< Previous 1 2 3 Next >
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From The Rosen Law Firm PA
Via GlobeNewswire
Surmodics to Participate in Upcoming Investor Conferences in March
From Surmodics, Inc.
Via Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
SRDX NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From The Rosen Law Firm PA
Via GlobeNewswire
Surmodics, Inc. (NASDAQ:SRDX) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 02/07/2023 -- An investigation was announced over potential securities laws violations by Surmodics, Inc. in connection with certain financial statements. 
Via SBWire
Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
From Surmodics, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From Rosen Law Firm
Via Business Wire
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
From Surmodics, Inc.
Via Business Wire
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18
From Surmodics, Inc.
Via Business Wire
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
From Surmodics, Inc.
Via Business Wire
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
From Surmodics, Inc.
Via Business Wire
Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing
From Surmodics, Inc.
Via Business Wire
6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe
From Surmodics, Inc.
Via Business Wire
6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe
From Surmodics, Inc.
Via Business Wire
Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022
From Surmodics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.